What is zavzpret, and how does it work for migraines?
Zavzpret (zavegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used to treat migraine attacks. As a CGRP blocker, it prevents CGRP from activating its receptor, which can reduce migraine pain and related symptoms during an attack.
How is it used during a migraine attack?
Zavzpret is taken during the migraine episode as an acute (attack-at-onset) treatment. Patients typically use it at the start of symptoms rather than as a daily preventive medicine.
What symptoms can improve?
Because it targets the migraine pain pathway through CGRP, zavegepant is intended to relieve the core migraine symptoms during an attack, including head pain and common associated symptoms people often get with migraines (such as sensitivity to light and sound, and nausea).
How does it compare with other migraine CGRP treatments?
Zavzpret is in the same “CGRP-targeting” family as other migraine options, but it’s positioned as an acute treatment. Some migraine patients use CGRP monoclonal antibodies for prevention, while treatments like zavegepant are used to stop an attack as it starts.
Who might consider zavzpret instead of triptans or older acute options?
People who cannot take triptans (because of side effects or medical reasons) or who prefer a non-traditional acute option may ask about CGRP receptor antagonists like zavzpret. Clinicians often consider it when patients need an effective acute treatment that works through the CGRP pathway rather than serotonin receptors.
Sources
No sources were provided with the question, and none are available in the supplied information.